CL-82198
Based on 9 publication(s) in Google Scholar
CL-82198 is a selective inhibitor of MMP-13. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs. CL-82198 is a pharmacologic treatment for preventing osteoarthritis (OA) progression.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.89%
- CAS No.: 307002-71-7
- Formule: C17H22N2O3
- Masse moléculaire:302.37
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Protease Inhibitor Library
HY-L147
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) CL-82198
More- Nat Biomed Eng. 2025 May 16. [Abstract]
- Cell Stem Cell. 2023 May 4;30(5):648-664.e8. [Abstract]
- Nat Commun. 2026 Jun 11. [Abstract]
- Nat Commun. 2022 Jul 11;13(1):4007. [Abstract]
- Mar Drugs. 2023 Jul 31;21(8):433. [Abstract]
- J Cell Physiol. 2019 Sep;234(9):15395-15406. [Abstract]
- Biol Reprod. 2025 Jan 17:ioaf012. [Abstract]
- bioRxiv. 2025 Sep 21:2025.09.18.677154. [Abstract]
- Patent. US20240271130A1.
Activité biologique
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:10-week-old C57BL/6J mice (performed MLI surgery)[4]
-
Dosage:1, 5, 10 mg/kg body weight
-
Administration:Intraperitoneal injection; every other day for 12 weeks
-
Result:Prevented and decelerated MLI-induced osteoarthritis progression.
Chemical Information
-
CAS No. 307002-71-7
-
Appearance Solid
-
Masse moléculaire 302.37
-
Formule C17H22N2O3
-
Color White to light yellow
-
SMILES
O=C(C1=CC2=CC=CC=C2O1)NCCCCN3CCOCC3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Biomed Eng
siRNA conjugate with high albumin affinity and degradation resistance for delivery and treatment of arthritis in mice and guinea pigs. [Abstract]2025 May 16. PMID: 40379798 -
Cell Stem Cell
Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal. [Abstract]2023 May 4;30(5):648-664.e8. PMID: 37146584 -
Nat Commun
Bone-derived Osterix+ osteolineage cells are a source of tumor-promoting myofibroblastic cancer-associated fibroblasts in breast cancer. [Abstract]2026 Jun 11. PMID: 42277024 -
Nat Commun
Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance. [Abstract]2022 Jul 11;13(1):4007. PMID: 35817773 -
Mar Drugs
Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer's Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13. [Abstract]2023 Jul 31;21(8):433. PMID: 37623714 -
J Cell Physiol
2019 Sep;234(9):15395-15406. PMID: 30710340 -
Biol Reprod
Collagen turnover during cervical remodeling involves both intracellular and extracellular collagen degradation pathways. [Abstract]2025 Jan 17:ioaf012. PMID: 39823285 -
bioRxiv
Myofibroblastic CAFs arising from bone-resident osteoblast precursors retain an osteolineage signature and support breast cancer progression via Osterix-mediated signaling. [Abstract]2025 Sep 21:2025.09.18.677154. PMID: 41279302 -
Solvant et solubilité
DMSO : 100 mg/mL (330.72 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Rath T et al. Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration. Oncol Lett. 2011 May;2(3):483-488. [Content Brief]
[2]. George J, et al. MMP-13 deletion decreases profibrogenic molecules and attenuates N-nitrosodimethylamine-induced liver injury and fibrosis in mice. J Cell Mol Med. 2017 Dec;21(12):3821-3835. [Content Brief]
[3]. Wohlauer M et al. Nebulized hypertonic saline attenuates acute lung injury following trauma and hemorrhagic shock via inhibition of matrix metalloproteinase-13. Crit Care Med. 2012 Sep;40(9):2647-53. [Content Brief]
[4]. Wang M,et al. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res Ther. 2013 Jan 8;15(1):R5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3072 mL | 16.5360 mL | 33.0721 mL | 82.6802 mL |
| 5 mM | 0.6614 mL | 3.3072 mL | 6.6144 mL | 16.5360 mL | |
| 10 mM | 0.3307 mL | 1.6536 mL | 3.3072 mL | 8.2680 mL | |
| 15 mM | 0.2205 mL | 1.1024 mL | 2.2048 mL | 5.5120 mL | |
| 20 mM | 0.1654 mL | 0.8268 mL | 1.6536 mL | 4.1340 mL | |
| 25 mM | 0.1323 mL | 0.6614 mL | 1.3229 mL | 3.3072 mL | |
| 30 mM | 0.1102 mL | 0.5512 mL | 1.1024 mL | 2.7560 mL | |
| 40 mM | 0.0827 mL | 0.4134 mL | 0.8268 mL | 2.0670 mL | |
| 50 mM | 0.0661 mL | 0.3307 mL | 0.6614 mL | 1.6536 mL | |
| 60 mM | 0.0551 mL | 0.2756 mL | 0.5512 mL | 1.3780 mL | |
| 80 mM | 0.0413 mL | 0.2067 mL | 0.4134 mL | 1.0335 mL | |
| 100 mM | 0.0331 mL | 0.1654 mL | 0.3307 mL | 0.8268 mL |
CL-82198 Related Classifications
HY-100359 Related Classifications
Powered by Bioz